Treatment of B-cell Prolymphocytic Leukemia with Normal TP53 (No Deletion or Mutation)
B-cell prolymphocytic leukemia (B-PLL) is stratified at diagnosis by TP53 status, which directly informs first-line management. Patients with confirmed normal TP53 — no TP53 deletion and no TP53 mutation — represent a distinct subgroup with its own recommended approach.
Clinical Scenario
This protocol addresses B-PLL in patients where TP53 is confirmed normal: no TP53 deletion detected and no TP53 mutation identified. This finding is the key qualifier for the management strategy described here.
Initial Management — Partial Overview
For patients presenting with an indolent disease course, an observational strategy forms part of the initial approach. The complete structured protocol — including criteria, thresholds, and full management guidance — is available via the link below.
References
DOI: 10.1182/asheducation-2015.1.361
- However, for the 50% of cases with normal TP53, a conventional chemo-immunotherapy approach with FCR or bendamustine and rituximab is reasonable.
- For T-PLL, first-line therapy is with intravenous alemtuzumab and for B-PLL is with combination chemo-immunotherapy for patients with normal TP53 and with alemtuzumab or BCR inhibitors for those with deletions or mutations of TP53.
- In those patients with either subtype, presenting with an indolent prephase, watchful monitoring is a reasonable approach.
- This situation may persist for a number of years without any clear evidence that early treatment intervention will be beneficial.
View source ↗